Concepedia

Karen Small

KS

20

Publications

933

Citations

15

H-Index

1991

Active since

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

The Ohio State University

Oregon Health & Science University

University of Maryland, Baltimore

Rutgers Cancer Institute

Karen Small is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, oncology, and pharmacotherapy.

Top concepts

Publications per year

1991–2017

20

Publications

20

Randomized Phase II Trial of the Cyclin-Dependent Kinase Inhibitor Dinaciclib (MK-7965) Versus Capecitabine in Patients With Advanced Breast Cancer

Monica Mita, Anil A. Joy, Alain C. Mita et al. · Clinical Breast Cancer · 2013 · 151 citations

, , +8

A first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies

John Nemunaitis, Karen Small, Paul T. Kirschmeier et al. · Journal of Translational Medicine · 2013 · 127 citations · Full text

Dinaciclib is a novel cyclin-dependent kinase inhibitor with significant clinical activity in relapsed and refractory chronic lymphocytic leukemia

Joseph M. Flynn, Jeffrey A. Jones, Amy J. Johnson et al. · Leukemia · 2015 · 114 citations · Full text

, , +7

Randomized phase 2 study of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus erlotinib in patients with non-small cell lung cancer

Joe Stephenson, John Nemunaitis, Anil A. Joy et al. · Lung Cancer · 2013 · 98 citations

, , +6

Clinical and laboratory studies of the novel cyclin-dependent kinase inhibitor dinaciclib (SCH 727965) in acute leukemias

Ivana Gojo, Mariola Sadowska, Alison Walker et al. · Cancer Chemotherapy and Pharmacology · 2013 · 93 citations · Full text

Rows per page

1–5 of 20